Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

doi:10.1038/s41416-025-03183-2

Article

Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

British journal of cancer - 1 Nov 2025

Hamza Abderaouf, Gestraud Pierre, Karimi Maryam, Tran-Dien Alicia, Syx Laurène, Vacher Sophie, Peretti Quentin, Lacroix Ludovic, Attignon Valery, Soubeyran Isabelle, Jézéquel Pascal, Planchard David, Melaabi Samia, Dailey-Chwalibóg Trenton, Jimenez Marta, Michiels Stefan, Servant Nicolas, Le Tourneau Christophe, Girard Nicolas, André Fabrice, Besse Benjamin, Kamal Maud, Barlesi Fabrice, Bièche Ivan

Abstract excerpt

BACKGROUND: Identifying molecular alterations specific to advanced lung adenocarcinomas could provide insights into tumour progression and dissemination mechanisms. METHOD: We analysed tumour samples, either from locoregional lesions or distant metastases, from patients with advanced lung adenocarcinoma from the SAFIR02-Lung trial by targeted sequencing of 45 cancer genes and comparative genomic hybridisation...

Read the complete abstract on PubMed

Topics

Humans
Adenocarcinoma of Lung

Molecular analysis of lung adenocarcinomas from the SAFIR02-Lung cohort reveals new metastasis-associated copy-number alterations including frequent mutant-specific KRAS-allelic imbalance and identifies CDKN2A homozygous deletions as an independent biomarker of poor prognosis.

Abstract excerpt

Topics

Related research